The role of cell division control protein 42 in tumor and non-tumor diseases: A systematic review

Junjie Fu1,5#, Bo Liu2#, Hao Zhang3,5#, Fangmei Fu3,5, Xiaohui Yang4,5, Linlin Fan3,5, Minying Zheng5, Shiwu Zhang5

1. Graduate School, Tianjin Medical University, Tianjin, 300070, P.R. China.
2. Medical Affairs Office, Tianjin Union Medical Center, Tianjin, P.R. China.
3. Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
4. Nankai University School of Medicine, Nankai University, Tianjin, P.R. China.
5. Department of Pathology, Tianjin Union Medical Center, Tianjin, P.R. China.

# These authors equally contributed to the paper.

Abstract

Rho-GTPases control a variety of cellular functions mainly by regulating microtubule and actin dynamics, affecting the cytoskeleton, and are important regulators of the structural plasticity of dendrites and spines. Members of the Rho-GTPase family include Ras-related C3 botulinum toxin substrate 1 (Rac1), RhoA (Ras homologous), and cell division control protein 42 (Cdc42). Cdc42 is involved in the regulation of a variety of tumor and non-tumor diseases through a cascade of multiple signaling pathways. Active Cdc42 can regulate intercellular adhesion, cytoskeleton formation, and cell cycle, thus affecting cell proliferation, transformation, and dynamic balance as well as migration and invasion of tumor cells by regulating the expression of effector proteins. Here we discuss the role of Cdc42 in promoting metastasis, invasion, epithelial-mesenchymal transformation and angiogenesis in malignant tumors. The significant role of Cdc42 in non-tumor diseases is also discussed. Since Cdc42 plays a central role in the development of various diseases, small molecule inhibitors targeting Cdc42 have important clinical significance in the prevention and treatment of these diseases.

Key words: cell division control protein 42; effector proteins; malignant tumors; benign diseases

Background

Rho-GTPases are a family of small GTP-binding proteins in the Ras superfamily, and their relative molecular weight is approximately 20-25 KD. Rho is found in all eukaryotes from plants to humans. Twenty members of the Rho family are divided into classic and non-classic groups. The peptide chain length of a member of the classic family is approximately 3-4 times that of a member of the non-classic family. The classic Rho-GTPase group includes RhoA (Ras homologous), Ras-related C3 botulinum toxin substrate 1 (Rac1), and cell division control protein 42 (Cdc42), which are modulated by the effects of Rho-specific guanine nucleotide exchange factor (GEF) and GTPase activating proteins (GAPs) and guanosine nucleotide dissociation inhibitors (GDIs). Rho-GEF regulates the exchange of GTP with GDP, thereby activating Rho-GTPases. Simultaneously, GAPs accelerates GTP hydrolysis and restores these proteins to an inactive state. Post-translational modification and the GTP/GDP cycle together regulate the biological activity of Rho-GTPases [1]. Cdc42 is one of the most important members of the Rho-GTP family and it is found first in fission yeast. It plays a crucial role in regulating the cell cycle, controlling gene transcription, regulating the cytoskeleton, cell movement, and polarization. Cdc42 activates the c-Jun NH2-terminal kinase (JNK) and mitogen-activated protein kinase (P38/MAPK)
pathways to control gene transcription. In addition, Cdc42 can activate neural Wiskott–Aldrich syndrome protein (N-WASP) and form a complex with actin monomer binding proteins, G-actin and actin-related protein 2/3 (Arp2/3), which promotes the aggregation of F-actin, and produces filopodia and induces cytoskeleton changes. P21-activated kinases (PAKs) are Cdc42 effector proteins, and they are cytosolic serine/threonine protein kinases, which can bind to a polarity scaffold protein or interact with Cdc42-directed GEF [2-7]. Here, we systematically reviewed the structure, functions, and small molecule inhibitors of Cdc42 in malignant tumor and non-tumor diseases, providing specific targets for the treatment of Cdc42-related diseases.

**Structure and function of Cdc42**

Cdc42 is a member of the Rho family with a molecular weight of 21 KD and is first discovered in yeast, Saccharomyces cerevisiae [8]. There are six kinds of Rho-GTPases in yeast, which are critical for maintaining cell polarity on the cell membrane. Cdc42 has two different isoforms, Cdc42a (also known as Cdc42p and Cdc42Hs) and Cdc42b (also known as brain-derived Cdc42p or G25K GTP-binding protein). Cdc42a is widely expressed in human tissues whereas Cdc42b is only expressed in the brain. The human Cdc42 gene is located on chromosome 1p36.1. The Cdc42 protein contains 191 amino acids and is mainly located in the mitotic spindle, cytokinesis central spindle, and intermediates.

Cdc42 is particularly important in yeast germination [9, 10] and polarization during growth, by promoting cytoskeleton remodeling and vesicle exocytosis, which are required for normal cell differentiation and movement [11, 12]. When Cdc42 function is lost, cells become round and budding growth is inhibited [12, 13]. In yeast cells, polarization of the cytoskeleton and the membrane transport system requires the isotropic and polarized distribution of Cdc42. Other studies have demonstrated that cytoskeleton and membrane transport systems have a negative feedback effect on Cdc42 distribution [14-16]. When yeast cells sprout, Cdc42 is first localized in the cortical region of the cell membrane and forms a complex with septin family members (Cdc3, Cdc10, Cdc11, and Cdc12). Then, septin family members are assigned to the specific growth site of the budding to participate in the generation of daughter cells [17, 18].

Cdc42 regulates microtubule cytoskeleton through microtubule reorganization, including asymmetric localization of the spindle. In addition, Cdc42 facilitates the development of the pancreas, blood cells, eyes, and skin [19]. Cdc42 is activated when it binds to GTP, but inactivated when it binds to GDP, and the activity of Cdc42 is regulated by GEFs, GAPs and GDIs [20]. The GAPs are designed to inactivate Cdc42 by hydrolyzing GTP into GDP. Most of the GAPs have non-specific effects on different small GTPases. GAPs includes Rga1, Rga2, and Bem3 [21]. Rga1 and Rga2 mainly regulate the interaction between Cdc42 and Ste20. Bem3 mediates the interaction between Cdc42 and Cla4 during cell division [21]. GDIs can block Cdc42 binding with GDP in cytoplasm and inhibit the activity of Cdc42. GDIs consist of an immunoglobulin-like C-terminal structure, and a flexible N-terminal domain that inhibits the exchange of GDP with GTP [22].

Active Cdc42 can regulate the expression of downstream effectors, and enhance cell proliferation, polarity, adhesion, and migration, as well as dynamic changes of the cytoskeleton [23]. Cdc42 accumulates in the cellular cortical cap to maintain cell polarity and regulates the polymerization and dissociation of cytoskeletal actin [24, 25]. Cdc42 can be activated when bradykinin binds to the corresponding receptors on the cell membrane. Activated Cdc42 can regulate the assembly of the plaque complex on the cell membrane and enhance the secretion of mastocytes as well as promote the transport of vesicles from the Golgi to the plasma membrane. Mutations rarely occur in Cdc42 [26]. When it mutates, it can combine with the γ subunit of the coatamer complex to regulate the material transport from the rough endoplasmic reticulum to the Golgi apparatus. Meanwhile, the γ subunit plays a continuous activating role in Cdc42-induced malignant transformation [27] (Fig. 1).

**Cdc42-related proteins and signaling pathways**

Cdc42 regulates the recombination of cytoskeletal proteins via P21-activated kinases (PAKs)

PAKs are downstream proteins of Cdc42 and are known for their roles in the cytoskeleton and are critical in the dynamic recombination of F-actin and tubulin. The PAKs family contains six proteins: PAK-1(α-PAK), PAK-2 (γ-PAK), PAK-3 (β-PAK) (group I), PAK-4, PAK-5, and PAK-6 (group II). Group I PAKs have an autoinhibitory domain and can interact with the kinase domain in a cis-autoinhibitory interaction. Binding of GTPase to PAKs disrupts this autoinhibition, leading to dimerization and trans-autophosphorylation of the two PAK monomers [28]. Group II PAKs have constitutive activation loop autophosphorylation, which is not affected by the binding of Rho GTPase [29]. Group II PAKs are...
activated by the dissociation of a proline-rich pseudosubstrate region from the kinase domain [30]. PAK-1 is important in the formation of lamellipodia and it is an interface between adhesion junctional complex (AJC) destabilization and increases motility [31]. Upon activation of Cdc42, PAK-1 phosphorylates LIMK and further inactivates coflin. During the G1 phase of the cell cycle, PAK-1 activates extracellular signal-regulated kinase (ERK) and nuclear factor κB (NF-κB) to increase cyclin D1 transcription. Late in the cell cycle, PAK-1 is activated in the centrosome, resulting in phosphorylation of Polo-like kinase 1 and Aurora A kinases, which regulates the mitotic process [32]. PAK-2 promotes cell survival by phosphorylating Bad and Bcl-2 [33]. On the other hand, apoptotic stimuli such as DNA damage can lead to caspase-mediated cleavage of PAK-2, resulting in the generation of p34 fragments. PAK-2-p34 activates JNK and inactivates MNK, leading to inactivation of the mitochondria-dependent death pathway [34]. Multiple human cancers are associated with overexpression of PAK-1, such as non-small-cell lung cancer [35], breast cancer, prostate cancer [36], pancreatic cancer, gastric cancer [37], colorectal cancer [38], and oral cancer [39]. Similarly, PAK-2 is highly expressed in gastric and ovarian cancers. In humans, deleterious mutations in the PAK-3 gene have been confirmed to be associated with X-linked non-syndromic intellectual disability through the JNK and P38 pathways [40]. Chung, E. Y. et al reported that inhibition of PAK2 could reduce CADM1-mediated stromal interactions and promote survival of adult T-Cell leukemia/lymphoma cells [41]. Moreover, PAK-4 gene amplification has been found in colorectal and pancreatic cancers via the phosphatidylinositol 3-kinase (PI3K) mutation [42, 43]. PAK-5 is dysregulated in ovarian cancer through the activation of the PI3K/AKT pathway, in cervical cancer via special AT-rich binding protein-1, and in glioblastoma via inhibition of early growth response protein 1 to upregulate matrix metalloproteinase 2 [44]. Finally, PAK-6 promotes cervical cancer progression through activation of the Wnt/β-catenin signaling pathway [45].

**Cdc42 binds activated Cdc42 kinase (ACK) to promote metastasis**

ACK is a non-receptor tyrosine kinase and functions downstream of growth factor receptors and has been implicated in survival, neuronal signaling, and androgen receptor activation through identification of its phosphorylation targets. The conformation of ACK binding to Cdc42 is significantly different from that of other CRIB effector proteins, all of which form a short segment of.
intermolecular β-sheet with Cdc42. Leu449, Ser-450 and Ala-451 residues in ACK are the key factors for binding to Cdc42 [46]. They interact with Cdc42 via helix α5 and the C-terminus of the protein. Leu174 is the specific determinant of ACK binding to Cdc42 [47]. In the N-terminal of ACK, Thr-35 can interact with both the γ-phosphate of GTP and Mg²⁺ to form a complex, which binds to Cdc42 in an initial and transient manner. The C-terminal region of the ACK contributes to the overall binding affinity through several scattered residues [46]. ACK1 is a member of the ACK family which consists of the N-terminal sterile topic domain, amino N-terminal Src-homology 3 (SH3) domain, kinase domain, and Cdc42/Rac interactive binding (CRIB), a proline-rich domain. Cdc42 can activate ACK1 by directly and specifically binding to it [48], which enables cells to bypass the blockade to major survival pathways to promote cancer progression and resistance to standard cancer treatments. In triple-negative breast cancer, ACK1 is highly expressed and triggers the activation of PI3K, which aggregates in the cell membrane and activates protein kinase B, enhancing the progression of breast cancer [49]. In addition, low expression of ACK1 can reduce the ubiquitination level of P53, thereby inducing G2/M phase arrest and apoptosis of gastric cancer cells, and preventing the occurrence of gastric cancer cells [50].

**Cdc42 enhances cell proliferation and migration by activating lipid kinases**

PI3K and PI5K are the core effector proteins of Cdc42/Rac. Cdc42/Rac and PI3K are mainly present in the mammalian system. PI5K and PI3K can produce PI2P and act as a second messenger to regulate the dynamic balance of the cytoskeleton. PI3K I has three homologous isoforms: PI3KCA, PI3KCB, and PI3KCD. PI3KCA mutations have been found in colon and non-small-cell lung cancer [51, 52]. However, among these three kinds of homologous forms, PIK3CB is more important in cancer than the other two. PIK3CB can be activated by Cdc42 and Rac1, and inactivation of PIK3CB can significantly suppress tumor proliferation, metastasis, and invasion in PTEN-deficient cancers [53].

Isoleucine-glutamine-motif containing GTPase-activating proteins (IQGAPs) promotes cell metastasis and invasion by binding to the activated Cdc42-GTP. IQGAPs are downstream effectors of Cdc42 and consist of two key regions, including a calmodulin binding IQ-motif and a GTPase activating protein related domain. Upregulated IQGAPs bind to the activated Cdc42-GTP [54] and promote cell metastasis and invasion [55], and the formation of the cytokinetic actin ring. IQGAPs can be divided in three groups: IQGAP 1, 2, and 3. IQGAP1 can intensify the regulatory ability of Cdc42p in the formation of the actin cytoskeleton [56, 57] and promote the occurrence and metastasis of carcinoma. IQGAP1 is associated with adhesion junctions and it can reduce E-cadherin mediated cell adhesion involved in tumor progression [58-62]. Studies have shown that IQGAP1 is highly expressed in cancer and is closely related to metastasis potential. Many studies have explored the Wnt/E-cadherin/β-catenin pathway downstream of IQGAP1 as a potential target for gastric cancer [63-65], and it has been reported that IQGAP1 gene knockout leads to gastric dysplasia in mice [66]. IQGAP1 binds to epidermal growth factor receptor (EGFR) and acts on epidermal growth factor (EGF) to activate AKT, weakening the effects of mammalian target of rapamycin complex, glycogen synthase kinaseM, and ERK1/2, inhibiting cell secretion, and promoting cell transformation [55, 67]. There are only a few studies on IQGAP2 and IQGAP3. IQGAP2 is 62% identical to IQGAP1 and has been reported to interact with both GDP- and GTP-bound forms, and may be a suppressor of cancer [57, 68]. IQGAP3 has rarely been reported and its specific role is unclear, although it has been suggested to be related to cell proliferation through the Ras/ERK signaling cascade [69].

**Formins can regulate actin dynamics by binding to activated Cdc42**

Formins are defined by a unique and highly conserved C-terminal formin homology 2 (FH2) domain and an N-terminal proline-rich formin homology 1 (FH1) domain [70]. FH1 has approximately 100 amino-acid and FH2 has approximately 130 amino acids. A highly structured homodimer of FH2 nucleates actin filaments. Formins can bind to activated Cdc42 via their FH1 domain. Furthermore, formins have different classifications and play different functions in different species. In budding yeast, the formin Bni1p associates with Cdc42p to regulate actin dynamics [71]. In *Drosophila melanogaster*, the gene encoding the formin protein Diaphanos is involved in cytokinesis [72]. In *Caeorhabditis elegans*, loss of the formin protein Cyk-1 function causes polar-body extrusion in embryonic mitosis [73]. The expression levels of formin-like 2 (FMNL2) are elevated in metastatic colorectal cancer cells [74] and decreased in hepatocellular carcinoma cells [75]. The reduction in the expression level of formin-homology-2-domain-containing protein through miRNA regulation inhibits the invasion of breast cancer [76]. When mutations occur in exon 4, which encodes for inverted FMNL2, the occurrence rate of autosomal dominant focal and segmental glomerulosclerosis is increased [77].
**Cdc42 activates neural Wiskott–Aldrich syndrome protein (N-WASP) to promote actin polymerization**

N-WASP is composed of GTPase-binding domain, CRIB and a VCA domain. Cdc42 interacts with and activates N-WASP. N-WASP then binds and activates the actin-associated protein 2/3 (Arp2/3) complex, leading to actin polymerization [78]. Cdc42-dependent actin assembly 1 (Toca-1) is involved in this process. Toca-1, Cdc42 and N-WASP form trimer complex, which promotes the assembly of Toca-1/N-WASP complex [79]. N-WASP also can be activated by binding to phosphatidylinositol bisphosphate-PIP2 through a pleckstrin-homology lipid-interaction domain. Hou et al. reported that N-WASP had the opposite function on tumor progression. Overexpression of N-WASP enhanced the invasion and migration of cervical cancer cells by regulating the P38/MAPKs signaling pathway [80]. In addition, overexpression of N-WASP correlates with the infiltration depth, lymph node metastasis, and pathological staging in esophageal squamous cell carcinoma (ESCC) [81]. However, Martin, T. A. reported that the expression of N-WASP was lower in breast cancer tissues compared with that in normal mammary tissues, and the invasiveness and migration of MDA-MB-231 cells were inhibited after transfected with N-WASP [82].

**Cdc42 regulates cell polarity via binding protease-activated receptors (PARs)**

The PAR protein family contains from PAR1 to PAR6. PAR3, PAR6 and atypical protein kinase C (aPKC) form a ternary complex named PARs complex that localizes asymmetrically in polarized cells, while PAR1 localizes to complementary domains. PAR1 phosphorylates PAR3 to block PAR3 binding to aPKC and inhibits cortical association of PAR3/PAR6/aPKC in Drosophila [83]. aPKC can phosphorylate PAR1 kinases to regulate localization and activity [84]. PAR5 promotes the interactions by binding phosphorylated forms of both PAR1 and PAR3. PAR4 is necessary for normal PAR asymmetries, and can drive polarization of single kidney intestinal epithelial cells after activated [85]. Cdc42 is activator of PAR3/PAR6/aPKC complex. Cdc42 controls formation of the PAR3/PAR6/aPKC complex, which plays a crucial part in Drosophila neuroectoderm and neuroblast development and mammalian epithelial cell apical-basal polarity and axon-dendrite polarity of neuron [86]. In addition, Cdc42 mediates the formation of PAR6/PKCζ complex, which regulates phosphorylation of GSK-3β to regulate the cell polarity.

**Cdc42 mediates cell proliferation, transformation, and apoptosis by activating mixed lineage kinase 3 (MLK3)**

MLK3 is a member of the mixed spectrum kinase family (MAPK). The MAPK family is composed of an amino N-terminal SH3 domain, a catalytic domain, leucine/isooleucine zipper motifs, and a CRIB motif. Activated Cdc42 interacts with MLK3 through CRIB motif and promotes the catalytic activity of MLK3. In a Cdc42-mediated MLK3 activation model, Cdc42 binds to the CRIB domain of MLK3 and blocks the association between the N-terminus of MLK3 and proline 495, thereby reducing the autoinhibition of MLK3 and forming an open structure that promotes autophosphorylation [87]. Activated MLK3 activates JNK by directing phosphorylation and activation of mitogen-activated protein kinase kinases (MKK) 4 and M KK7. Meanwhile, MLK3 is involved in cell proliferation, transformation, and apoptosis via mitogen-dependent activation of ERK [88], and promotes the invasion and metastasis in non-small cell lung cancer, breast cancer, melanoma, and ovarian cancer cells [89-91].

**MAPK is involved in the regulation of Cdc42 activity**

MAPK signaling pathway consists of MAPKKK, MAPKK and MAPK, and they undergo phosphorylation in turn in response to internal and external stimuli. When these three kinases are activated, phosphorylated MAPK (ERK) will migrate to the nucleus and phosphorylate nuclear transcription factors to sequentially phosphorylate of specific transcription factors and then initiate transcription process [92]. There is a functional interaction between Cdc42 GTPase and MAPK Sty1. The function of MAPK Sty1 promoting Cdc42 dispersal is independent of stress-induced gene expression via Atf1 or plo1-mediated regulation of cell polarity. The amino acid sequence of Cdc42 has a single consensus site for MAPK phosphorylation. Mutavchiev et al found that MAPK may negatively regulate the coupling of the Cdc42 module to cell-polarity landmarks [93].

**Cdc42 and Eph–Ephrin signaling pathway**

EphA regulates actin cytoskeletal dynamics through Rho family GTPases. The Rho-GEF ephexin, associates with EphA receptors can activate Cdc42. After EphA binding, ephexin becomes phosphorylated and increased Rho activation, which leads to a destabilization of the actin cytoskeleton. A number of Rho family GAPs and GEFs are activated by EphA forward signaling. The GAP α2-chimaerin is the major GAP downstream of EphA4 in midline...
guidance processes. α2-chimaerin binds to the activated EphA4 receptor [94]. Ephexin is a GEF that when bound to EphAs in the absence of ephrin-A binding causes activation of Rho, Cdc42, and Rac1 [95]. When EphAs are bound to ephrin-As, ephexin changes its activity, which increases the Rho activation and decreases the activation of Cdc42 and Rac1.

**Cdc42 and malignant tumors**

Although Cdc42 is first found in yeast, where it plays an important role, it is equally important in the occurrence and development of various human malignant tumors. In most human normal tissue cells, Cdc42 expression is low/medium both at the mRNA and protein level. However, in tumor cells, the high expression of activated Cdc42, abnormal ubiquitin ligase, and EGFR degradation inhibition result in malignant tumor progression [96]. Cdc42 activates downstream actin-related proteins and induces fasciculation of F-actin in the filamentous pseudopodia of the cell, adheres to the extracellular matrix, and promotes cell movement. In ovarian cancer, breast cancer, bladder cancer, and prostate cancer, the downstream PAKs of Cdc42 are highly expressed [97, 98]. Additionally, the growth of tumor cells usually consumes a lot of glucose and glutamine under aerobic conditions, which is supplemented by the tricarboxylic acid cycle, which enables sustained biosynthesis of lipids, proteins, and nucleic acids and promotes cell proliferation. Mutation of Cdc42 can increase the activity of glutamine in the mitochondria, which can cause continuous metabolism of glutamine and change the metabolic mode of tumor cells, leading to malignant development [99] (Fig. 2). Hadad, S. et al reported that metformin reduced the incidence of breast cancer and enhanced response to neoadjuvant chemotherapy in diabetic women by upregulating TGFB and MEKK and downregulating Cdc42 [100].

**Cdc42 promotes proliferation of cancer cells**

Cdc42 is generally upregulated and involved in the activation of cell signaling pathways, including PAK and N-WASP, which are closely related to the malignant proliferation of tumor cells [101]. Cdc42 can enhance tumor cell proliferation by regulating the expression of EGFR in gastric cancer [102] [103]. Meanwhile, the proliferation of breast cancer cells requires the nutrition supply of new blood vessels and the expression of angiogenic factors (EGF, vascular endothelial growth factor (VEGF), interleukin (IL-6, and IL-8) which are regulated by Cdc42 [104]. In colorectal cancer, Cdc42 is involved in cancer cell proliferation through the PAK-mediated tight junction and AJC. The functional tight junction and AJC inhibit cell proliferation and lead to the destruction of intercellular adhesion, indicating that Rho-GTPases can directly participate in regulation of...
proliferation. The deficiency of Cdc42 can lead to an imbalance in the proliferation and apoptosis of breast epithelial cells by inactivating cyclin D1, which hinders the G1/S transition. Second, the lack of Cdc42 prevents the formation of a complex with PAR and PKC, which results in the failure of apical polarity formation in mammary epithelial cells [105] and changes in spindle orientation. Additionally, in breast cancer and colorectal cancer, Cdc42 regulates anti-apoptotic signals through the anti-cancer gene p53 [106], anti-apoptotic Bcl-2 family members, proto-oncogene C-myc, and fatty acid synthase, supporting breast cancer cells continuous growth [107].

**Cdc42 promotes epithelial-mesenchymal transition (EMT)**

EMT is a major driver of cancer cells invasion and metastasis. EMT allows cancer cells to metastasize and break the adhesion between cells. EMT plays an important role in physiological and pathological processes, including the promotion of wound healing, tissue fibrosis, and cancer progression. EMT and the formation of new blood vessels are the basis of tumor metastasis. EMT is a complex cellular process characterized by the loss of E-cadherin and adhesion complex, and is regulated by EMT-induced transcription factors (such as Snail, Slug, and Twist) [108, 109]. Besides E-cadherin, β-catenin, α-catenin, and p120-catenin are involved in intercellular adhesion. P120-catenin dissociates from adhesion junctions and localizes in the cytoplasm where it can interact with Cdc42, leading to enhanced metastasis and invasion capabilities of cancer cells. Moreover, p120-catenin activates Rac1 and Cdc42 indirectly by activating the guanine nucleotide exchange factor Vav2. A study by Bisson N showed that inhibition of Rhov, Rac1, and PAK could inhibit EMT transcription factors in *Xenopus laevis*, indicating that Rhov, Rac1, Cdc42, and their downstream effectors PAK-1 was involved in EMT [110]. Cdc42 also participates in the EMT process through IQGAP1. When Cdc42 is inactivated, IQGAP1 binds to β-catenin, resulting in the loss of α-catenin-linked actin filaments and reduces adhesion between cells. Active Cdc42 binds to IQGAP1, resulting in reduced Cdc42/β-catenin interaction [111]. Interferon regulatory factor 4 binding protein (IBP) can mediate the activation of RAC1, RhOA, and Cdc42, to regulate actin cytoskeletal rearrangement and produce MMPs. IBP can mediate the phenotype of EMT by down-regulating the expression of E-cadherin and keratin and up-regulating the expression of N-cadherin to increase the invasion and metastasis ability of breast cancer cells [112].

**Other proteins involved in Cdc42 regulating the invasion and metastasis of cancer cells**

During colorectal cancer progression, there are two patterns of metastasis including mesenchymal and amoeba metastasis. The switching of tumor cell metastasis patterns depends on the response to Rho-GTPases [113]. Cdc42 induces actin polymerization at the front edge of the lamellar lipid membrane to promote the metastasis of colorectal cancer cells. Tight junctions, adhesion junctions, and AJC contribute to form the connections of gastrointestinal epithelial cells. Among the effector proteins of Rho-GTPases, Rho-associated protein kinases are involved in the decomposition of AJC and regulate cell polarity and metastasis of colorectal cancer cells. Rho-GTPases can affect adomatous polyposis coli (APC) and APC activates the specific GEF for Cdc42 [114]. Minard, M.E, et al have shown that triggering Tiam1, a GEF of both Rac and Cdc42, can induce the downregulation of E-cadherin and increase the expression of vimentin to increase the migration ability of colorectal cancer cell [115]. In glioma, Slit homolog protein/roundabout homolog 1 (Slit-Robo1) can reduce the activity of Cdc42 to inhibit the invasion of cancer cells [116]. TNF-like weak inducers of apoptosis (TWEAK) and fibroblast growth factor inducible-14 (Fn14) can activate Ect2-GEF and Cdc42 [117] to regulate the metastasis and invasion of glioma [117]. The receptor proteins tyrosine phosphatase and dynamin 2 also participate in the metastasis of glioma cells and activate Rac1 and Cdc42. Zhang, et al. reported that the loss of Cdc42-specific Rho GTPase-activating protein 21 caused morphological changes in glioma cells, and increased Cdc42 activity and cell migration ability. The downstream of the Slit2/Robo1 signaling pathway is Slit-Robo1 GTPase-activating protein (srGAPs) including srGAP1, srGAP2, and srGAP3. SrGAP1 interacts with the intracellular domain (CC3 motif) of Robo1 during neuronal migration, leading to the repelling activity of Slit and the inhibition of Cdc42 [118]. When Slit2 is overexpressed, the GTPase activity of Cdc42 decreases, which inhibits Cdc42 expression [118].

**Cdc42 promoted the migration and invasion of daughter cells derived from PGCCs**

We previously reported that polyploid giant cell cancer cells (PGCCs) could be induced and purified by cobalt chloride. PGCCs were found to be in a dynamic equilibrium with diploid cancer cells and could be formed through endoreduplication or cell fusion [119]. They reverted to regular cancer cells via asymmetric cell divisions, including the splitting, budding, or burst-like mechanisms commonly used in...
the replication of low-level eukaryotes, plants, and viruses [85]. PGCCs produce daughter cells via asymmetric cell division and the daughter cells have strong ability of migration, invasion and proliferation [119]. In an unpublished paper, we confirmed that Cdc42 involved in process of PGCCs producing daughter cells. Daughter cells derived from PGCCs have strong abilities of proliferation, migration and invasion [120]. The results of western blot showed that the expression of Cdc42 and the downstream protein PAK1 in PGCCs and their daughter cells treated by cobalt chloride was significantly higher than that of the LoVo and Hct116 control cells.

Cdc42 facilitates tumor angiogenesis

Hypoxic inducible factor (HIF), cyclin D1, IL-6, IL-8, fibroblast growth factor (FGF), and integrins, are associated with the process of angiogenesis. HIF induces gene transcription of vascular endothelial growth factor, nitric oxide synthase, platelet-derived growth factor-β, and angiopoietin-2 during EMT [121]. Hypoxia increased the expression of Cdc42, Rac1, and RhoA in human cancer cells and microvascular endothelial cells [122]. During angiogenesis, the proliferation of endothelial cell requires full factor signal transduction and integrin signaling to activate cyclin D1, which is a cell cycle-related protein. At the same time, activation of cyclin D1 requires ERK activation. RhoA, Rac1, and Cdc42 are necessary to maintain the activity of ERK [123]. IL-6 and IL-8 can promote tumor growth and angiogenesis [124, 125], [126, 127], which can be induced by hypoxia and upregulated VEGF mRNA expression [128]. Increased Cdc42 activity increases the activation of NF-κB, resulting in increased accumulation of IL-6 mRNA and IL-8 mRNA and protein [129, 130]. In addition, FGF is an important angiogenic protein, and Cdc42 increases FGF1 expression by binding to the Ets site of the FGF1D promoter [131], stimulating the FGF1 gene promoter region. Integrins and the Rho signal transduction pathway are interrelated at many levels and together promote the development of angiogenesis.

Cdc42 and human benign diseases

Cdc42 participates in the regulation of a variety of biological processes. The increased expression of Cdc42 can promote the proliferation, invasion, and migration of cancer cells, and accelerate malignant progression of cancer. Overexpression or loss of Cdc42 also contributes to the development of some benign diseases through the same or similar signaling pathways as malignant tumors, such as insulin secretion, insulin resistance, airway inflammation and neurodegenerative diseases (Fig.3).

Cdc42 is involved in diabetes via regulating PAKs and IQGAP

The constitutive activity of Cdc42 can interfere with the differentiation of β cells, inducing the rise of blood glucose sometimes leading to hyperglycemia. In normal human cells, Cdc42 regulates the formation of normal islet morphology associated with β cell function and proliferation [132], which is mainly accomplished by regulating the downstream signaling molecules PAK1 and cyclin D1. Cdc42 regulates IQGAP1, activates Rab27a and coronin-3, and adjusts the redistribution of Rab27a and coronin3 to regulate the function of cell membrane endocytosis [133, 134]. The decrease in Cdc42 can inhibit the activity of PAK1 and increase the risk of insulin resistance [135, 136]. The decrease in Cdc42 activity and G protein-coupled receptor kinase 2 (GRK2) activity leads to the downregulation of insulin-stimulated glucose transporter 4 translocation, which ultimately leads to the inhibition of insulin-stimulated glucose transport and insulin desensitization [137]. Podocytes affect cytoskeletal actin dynamics and Cdc42 can regulate the expression of actin. When Cdc42 is dysfunctional, the stability and rearrangement of the cytoskeleton can lead to adhesion impairment in podocytes. The expression of high-sensitivity Cdc42 activates SAPK/P38 pathways to promote mesangial cell hypertrophy and migration [138]. Furthermore, loss of Cdc42 is also an important cause of renal tubulointerstitial fibrosis in congenital nephrotic syndrome and glomerular sclerosis [139].

Cdc42 dysregulates transducer and activator of transcription 6 (STAT6) and GATA-binding protein 3 (GATA3) to lead airway inflammation

Signal transducer and activator of transcription 6 (STAT6) can be activated by IL-4 and IL-13. GATA3 has been demonstrated to play important roles in innate lymphoid cells and to regulate T cell development, proliferation, and maintenance, in addition to controlling Th2 differentiation [140, 141]. The lack of Cdc42 in T cells can significantly decrease the activation and expression of STAT6 and GATA3. These two transcription factors are crucial for the secretion of IL-4 and the differentiation of Th2 cells. When Cdc42 is deficient, the homeostasis of peripheral T cells is disrupted, and the activation of CD4+Foxp3+ reduces regulatory T cells, inhibits the development of thymus cells, and suppresses the differentiation of Th1/Th17 cells [142, 143]. Cdc42 regulates both cell activation and clonal expansion in CD4+ T cells. In contrast, Cdc42 regulates clonal expansion but not activation in CD8+ cells [144].
**Figure 3.** The roles of Cdc42 in non-tumor diseases. Cdc42 activates stress-activated protein kinase and P38, which causes diabetic nephropathy. Cdc42 activates GATA3 and STAT6, leading to airway inflammation. Cdc42 induces insulin endocytosis by activating Rab27a and coronavirus 3. Cdc42 binding GTP activates actin and causes insulin secretion. Cdc42 causes aging of hematopoietic stem cells. Cdc42 activates the Par complex, involved in the self-renewal of stem/progenitor cells.

**Cdc42 dysregulates the neurite formation and results in neurodegenerative diseases**

Endo, M., J.E. et al. confirmed that Cdc42 could stimulate the activity of mTOR complex 1, thereby up-regulating the transcription factors required for the formation of neural precursor cells in normal brain tissue. The brain-specific Cdc42 isoform, Cdc42b, is essential for promoting the transformation of neural progenitor cells into neurons. Cdc42b and activated ACK jointly down-regulated mTOR expression and promoted neuronal differentiation [145]. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common neurodegenerative diseases [146]. In normal organisms, Cdc42 requires activation of multiple GEFs (Dbs, intersectin, Prex1, Tiam1, and Vav1-3) to promote neurite formation, axon growth and branching, spinal column formation, and neuronal differentiation [20]. The overexpression of intersectin alter the Cdc42 mediated endocytosis, leading to the increased expression of Cdc42 in the prefrontal cortex of AD patients [147]. The Cdc42/PAK complex controls neurite growth and filopodia formation. Cdc42 can promote the activation of PAK and PAK stimulates LIMK and inhibits the depolymerization of actin filaments. The imbalance of PAK/LIMK axis is the key to the formation of AD [148]. In AD, the elevation of neuronal isoprenoid levels induces prenylation of Cdc42, which can activate GSK-3β, resulting in phosphorylation of Tau [149]. In PD, synaptic dysfunction may cause neurons death by segregation of Cdc42/Rac in Lewy bodies. Recent study has shown that topoisomerase Iβ downregulation may cause neurodegeneration through dysregulation of Rho-GTPases leading to PD-like pathology, which may be a potential direction in the prevention and treatment of PD in the future [150]. In addition, Huntington’s disease is a progressive neuropsychiatric disorder associated with motor dysfunction due to neurotoxicity caused by the aggregation of huntingtin (Htt) protein. Cdc42 and Rac effector proteins promote Htt aggregation and exacerbate the effects of the disease. Damage to Cdc42 may also affect motor neuron death in amyotrophic lateral sclerosis [151].

**Small molecule inhibitors of Cdc42**

There are many small molecule inhibitors of Cdc42. However, there are few clinical trials about Cdc42 inhibitors and most studies of cdc42 inhibitors are performed in vivo and in vitro in pre-clinical settings. Commonly used small molecule inhibitors of Cdc42 are listed in Table-1.

**Azathioprine decreases Cdc42 activity via blocking Rho-GEF**

Most of the current inhibitors have been developed interact with GEF and bind nucleotides to inhibit Cdc42. Azathioprine (AZA) 1 and AZA197 are GEF interaction inhibitors. AZA1 can effectively inhibit the activation of Cdc42 and Rac1, reduce the signal transduction of the PAK pathway, and inhibit tumor growth. The main mechanism of AZA197 anti-tumor effect is through the inhibition of cell proliferation and induction of apoptosis. AZA197 destroys the interaction between Cdc42 and GEF and specifically inhibits the activity of Cdc42. AZA197 inhibits the proliferation, migration, and invasion of cancer cells in colon cancer and prostate cancer [152].
It can reduce the activity of PAK and ERK signaling pathways and weaken the expression of cyclin D1, thus reducing the invasion and growth of colon cancer tumors. AZA197 treatment results in the transformation of the actin cytoskeleton and cellular morphology and prevents filopodia formation in colon cancer cells. AZA197 can effectively modulate PAK/ERK signaling transduction and interfere with colon cancer cells. AZA197 can effectively modulate morphology and prevents filopodia formation in transformation of the actin cytoskeleton and cellular protrusions. MBQ167 is a GEF interaction inhibitor. Casin targets regulation of Cdc42. Secramine alleviates Cdc42 effect by blocking Rho-GDI. ML141 reduces Cdc42 activity through interfering GTP binding domain. ZCL inhibits the progression of cancer by preventing EGFR/kRas.

**Table 1. Small molecule inhibitors of Cdc42.**

| Inhibitors | Function | References |
|-----------|----------|------------|
| AZA1      | AZA1 can interact with GEF and bind nucleotides to inhibit the activation of Cdc42 and Rac1. | [152, 153] |
| AZA197    | AZA197 inhibits cell proliferation and induces apoptosis. | |
| Casin     | Casin blocks PIP2 on the Cdc42/RhoGDI complex and inhibits Cdc42 nucleotide exchange and disrupts intersectin. | [154-156] |
| MBQ167    | MBQ167 can inhibit Rac and Cdc42. | [158] |
| FRAX486, 597, 1036 | PK small-molecule inhibitors | [157, 159-162] |
| G-5555, NOV3, AZ137-0539 | PK-specific inhibitors | |
| ZCL       | ZCL inhibits the progression of cancer by preventing EGFR/kRas. | [163, 164] |
| ML141     | ML141 reduces Cdc42 activity through interfering GTP binding domain. | [165-167, 169, 174] |
| Secramine | Secramine alleviates Cdc42 effect by blocking Rho-GDI | [170-173] |

**Casin targets regulation of Cdc42**

Casin controls GEF activity by blocking PIP2 on the Cdc42/RhoGDI complex and inhibiting Cdc42 nucleotide exchange and further targeted regulation of Cdc42 [154]. It disrupts intersectin, thereby inhibiting the activation of Cdc42. Study have shown that in the hematopoietic stem cell system, the application of Casin can transform aging hematopoietic stem cells into young hematopoietic stem cells due to the inhibition of Cdc42 function[155]. Casin is widely used in cell processing, and different concentrations play different roles [156].

**MBQ167 is a GEF interaction inhibitor**

MBQ167 is an effective dual inhibitor of Rac and Cdc42. In *silico*, MBQ167 is shown to bind to the Asn 39 side chain of Cdc42 and Rac to form an H bond, which is thought to inactivate the GEF binding region [157]. MBQ167 shows improved efficacy in metastatic breast cancer cells by inhibiting Rac activity and Cdc42 activity. MBQ167 rearranges the actin cytoskeleton and adhesion plaques, resulting in loss of cell polarity and attachment to the extracellular matrix, as well as in a significant reduction in Rac-mediated lamellipodia/invadopodia and Cdc42-induced microtubules and filamentous pseudopodia. MBQ167 can effectively inhibit the activity of overall PAK because it induces a decrease in the activating phosphorylation (Y507/T508) of the direct PAK substrate LIMK and the inactivating phosphorylation (S3) of cofilin (actin depolymerization factor, a downstream effector of LIMK) [158]. In addition, a group of PAK small-molecule inhibitors (such as FRAX486, 597, and 1036) and PAK-specific inhibitors have a similar function with favorable clinical efficacy (such as G-5555, NOV3, and AZ137-0539) [157, 159, 160]. FRAX486 reduced audiogenic seizures. FRAX597 inhibits the proliferation, invasion, and metastasis of pancreatic cancer cells and Schwannoma cells, and decreases the progression of pancreatic cancer and neurofibroma type 2 [161, 162].

**ZCL inhibits the progress of cancer by preventing EGFR/kRas**

ZCL compounds inhibit cell proliferation and cell cycle progression by inhibiting the EGFR-kRas signaling pathway. Study has shown that ZCL278 plays an important role in inhibiting the invasion and metastasis of pancreatic cancer cells [163]. ZCL278 can form two hydrogen bonds with Thr35 and Asp57, and hydrophobic interactions with Val36 and Thr35 of Cdc42. ZCL278 has a markedly increased affinity with Cdc42 in its GEF-complex conformation, promoting the binding of GTP and Cdc42. Additionally, ZCL278 can interact with Cdc42 in the corresponding intersectin groove, thereby acting as an antagonist and agonist. ZCL278 can act as a partial agonist for Cdc42, whereas ZCL367 is a Cdc42 inhibitor. ZCL367 inhibited the metastasis of lung cancer cells A549 and prostate cancer cells PC3 in a time-dependent manner. Compared with ZCL278, ZCL193, ZCL251 ZCL254, ZCL257, ZCL269, ZCL367 can effectively restrain microspike/filopodia formation of 3T3 cells. ZCL367 can form three hydrogen bonds with Asp38, Asn39, and Asp57, and hydrophobic interactions with Phe56 and Val36 of Cdc42. Because ZCL367 forms more hydrogen bonds than ZCL278, it is able to interact more strongly with Cdc42. ZCL367 has good selectivity to Cdc42 *in vitro* and inhibits the interaction between Cdc42 and intersectin in lung cancer A549 cell lysates. ZCL278 is also a GEF interaction inhibitor. It can destroy the interaction of ITSN with Cdc42 and on the surface of the Cdc42 Phe56 wide-ranging combination, inhibiting migration in the PC-3 cell line without destroying cell vitality and suppressing cellular invasion and migration in pancreatic cancer cell lines [164].
ML141 reduces Cdc42 activity through interdicting GTP binding domain

ML141, is a competitive inhibitor of Cdc42 activity. It is a type of nucleotide inhibitor and non-steroidal anti-inflammatory drug (NSAID)-related compound, which can specifically block the GTP binding domain [165]. It can reduce filopodia formation in fibroblasts induced by bradykinin, and significantly inhibit Cdc42 activity [165]. CID44216842 is a homologous analog of ML141. The two drugs can effectively inhibit the migration of ovarian cancer cells [166]. ML141 can also inhibit metastasis of breast cancer cells [166]. Other NSAIDs, such as R-Ketorolac and R-Naproxen, can reduce the adhesion, metastasis, and invasion of ovarian cancer cells by inhibiting Cdc42 activity [167, 168]. Ketorolac, a kind of Cdc42 specific inhibitor, can potentially contribute to the observed survival benefit in women after ovarian cancer surgery. Ketorolac has a novel pharmacologic activity by inhibiting Rac1 and Cdc42, potentially contributes to the survival benefit in women with ovarian cancer and reduces ovarian cancer-specific mortality [169].

Secramine alleviates Cdc42 effect by blocking Rho-GDI

Secramine inhibits actin assembly in vitro, which is stimulated by PIP2 and mediated by the Cdc42/Toca-1/N-WASP/Arp2/3 signaling pathway [170]. Secramine belongs to the RhoGDI modulators and exerts its function strictly depending on the presence of RhoGDI1. RhoGDI1 can promote the solubility of prenylated Cdc42 and act as a shuttle for the transport of GDP-Cdc42 or GTP-Cdc42 between the cytosol and target membranes [171]. Secramine isolates Cdc42 and blocks isoprene Cdc42 from the cell membrane. It inhibits protein transport from the Golgi body to the plasma membrane [172]. Secramines A and B do not require nucleotide exchange for nonprenylated Cdc42 because they do not interfere directly with the GEF, and do not compete with nucleotide binding. As a Cdc42-GDP-RhoGDI1 complex, Secramines A and B decrease the membrane association of prenylated Cdc42 (GDP) that is present in PIP2 liposomes. Secramine A inhibits Cdc42 activation and reduces the possibility of Cdc42 binding to the membrane by dissolving the PIP2 liposome or binding to the PIP2 inositol head [173].

Conclusion

In this review, we described the structure and functions of Cdc42 and its family, analyzing its major regulatory effectors, and summarizing the drugs that specifically target Cdc42 in disease treatment. Cdc42 is widely involved in the regulation of human malignant and non-neoplastic diseases, and plays an important role in the invasion and metastasis of tumors, cell proliferation, and cell polarity. Furthermore, the potential regulatory role of Cdc42 in non-tumor diseases and malignant diseases is discussed. So far, although some inhibitors of Cdc42 protein have been developed, few drugs can be used in clinical treatment, and the regulatory mechanisms of Cdc42 in a variety of diseases need to be further explored in order to achieve effective treatment.

Acknowledgments

This work was supported in part by grants from the National Science Foundation of China (#82173283 and #82103088), and Foundation of committee on science and technology of Tianjin (#20JCJJC01230). We acknowledge the editage service for the manuscript language editing.

Abbreviations

Rac1: ras-related protein 1; Cdc42: cell division control protein 42; ACK1: activated Cdc42 kinase 1; IQGAPs: IQ motif-containing GTPase-activating proteins; GEF: guanine nucleotide exchange factor; GAPs: GTPase activating proteins; GTPase: GTPase activating proteins; Rnd: Rho-related GTP-binding protein; NF-kB: nuclear factor kB; JNK: c-Jun NH2-terminal kinase; MAPK: mitogen-activated protein kinase; N-WASP: neural wiskott–aldrich syndrome protein; Arp2/3: actin-related protein 2/3; PAKs: p21-activated kinases; GDIs: GTPase dissociation inhibitors; PAR: proteinase-activated receptor; PI3K: phosphoinositide 3-kinases; ERK: extracellular signal-regulated kinase; Toca-1: Cdc42-dependent actin assembly 1 (Toca-1); MAP: microtubule-associated proteins; MKK: mitogen-activated protein kinase kinases; EMT: epithelial-mesenchymal transformation; HIF: hypoxic inducible factor; IL: interleukin; FGF: fibroblast growth factors; EGFR: epidermal growth factor receptor; ROCK: Rho-associated protein kinase; Asef: APC-stimulated guanine nucleotide exchange factor; APC: adenomatous polyposis coli; SmurF1: smad ubiquitylation regulatory factor-1; GSK3: glycogen synthase kinase; ERK1/2: extracellular signal-regulated kinase 1/2; Slit-Robo1: Slit homolog protein/roundabout homolog 1; TWEAK: TNF-like weak inducer of apoptosis; Fn14: fibroblast growth factor inducible-14; srGAPs: Slit-Robo1 GTPase activating protein; STAT6: signal transducer and activator of transcription 6; GATA3: transcription factor GATA-binding protein 3; Abeta: amyloid-β peptides 1-40 and 1-42; LIMK: LIM kinase; AD: alzheimer disease; PD: parkinson’s disease; NSAIDs: non-steroidal anti-inflammatory drugs.
Competing Interests
The authors have declared that no competing interest exists.

References
1. Haga RB, Ridley AJ. Rho GTPases: Regulation and roles in cancer cell biology. Small GTPases. 2016; 7: 207-21.
2. Bøse I, Irazoqui JE, Moskov JI, Bardes ES, Zyla TR, Lew DJ. Assembly of scaffold-mediated complexes containing Cdc42p, the exchange factor Cdc24p, and the effector Cla4p required for cell cycle-regulated phosphorylation of Cdc24p. J. Biol Chem. 2001; 276: 7176-86.
3. Butty AC, Ferrinjautet N, Petit A, Jaquemoud M, Segall JE; Hofmann K, et al. A positive feedback loop stabilizes the guanine-nucleotide exchange factor Cdc2 at sites of polarization. EMBO J. 2002; 21: 1565-76.
4. Endo M, Shirowuzu M, Yokoyama S. The Cdc42 binding and scaffolding activities of the fission yeast adaptor protein Scd2. J. Biol Chem. 2003; 278: 843-52.
5. Irazoqui JE, Gladfelter AS, Lew DJ. Scaffold-mediated symmetry exchange factor Cdc24 at sites of polarization. EMBO J. 2002; 21: 1565-76.
6. Ito T, Matsui Y, Ago T, Ota K, Sumimoto H. Novel modular domain PB1 recognizes PC motif to mediate functional protein-protein interactions. J Biol Chem. 2001; 276: 7176-86.
7. Karpova TS, Reck-Peterson SL, Elkind NB, Mooseker MS, Novick PJ, et al. A positive feedback loop stabilizes the guanine-nucleotide exchange factor Cdc2 at sites of polarization. EMBO J. 2002; 21: 1565-76.
8. Johnson ES, Blobel G. Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins. J Cell Biol. 1999; 147: 981-94.
9. McCroskery S, Chaudhry A, Lin L, Daniels MP. Transmembrane agrin regulates filopodia in rat hippocampal neurons in culture. Mol Cell Neurosci. 2006; 33: 15-28.
10. Etienne-Manneville S. Cdc42—the centre of polarity. J. Cell Sci. 2004; 117: 1291-300.
11. Johnson DI, Pringle JR. Molecular characterization of CDC42a, a Saccharomyces cerevisiae gene involved in the development of cell polarity. J. Cell Biol. 1999; 141: 115-23.
12. Johnson DI, Cdc42. An essential Rho-type GTPase controlling eukaryotic cell polarity. Microbiol Mol Biol Rev. 1999; 63: 54-105.
13. Estravis M, Rincón SA, Santos B, Perez P. Cdc42 regulates multiple membrane traffic events in fission yeast. Traffic. 2011; 12: 1744-58.
14. Irazoqui JE, Howell AS, Theesfeld CL, Lew DJ. Opposing roles for actin and Myo2p in polarized secretion and growth of Saccharomyces cerevisiae. Cell Biol. 2001; 20: 3938-46.
15. Chen LM, Hobbie S, Galan JE. Requirement of CDC42 for gamma-PAK suppresses programmed cell death of BALB3T3 fibroblasts. J. Biol Chem. 2001; 276: 16624-32.
16. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res. 2005; 15: 36-42.
17. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J. 2003; 378: 437-48.
18. 50. Xu SH, Huang JZ, Chen M, Zeng M, Zou FY, Chen, et al. Amplification of PAK1 correlates with Abrassent Expression of EMT Markers and Poor Prognosis in Non-Small Cell Lung Cancer. J. Cancer. 2017; 8: 1484-91.
19. Al-Azayzih A, Gao F, Somanath PR. P21 activated kinase-1 mediates transforming growth factor beta-induced proliferation of breast cancer cells through the mesenchymal transition. Biochem Biophys Acta. 2015; 1853: 1229-39.
20. Wang G, Song Y, Liu T, Wang C, Zhang Q, Liu F, et al. PAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesis. Oncotarget. 2015; 6: 9877-86.
21. Al-Maghribi J, Emam E, Gomaa W, Al-Qaydy D, Al-Maghribi B, Buhlmeida A, et al. Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma. Int J Clin Exp Pathol. 2015; 8: 15895-902.
22. Bienvenu T, des Portes V, McDonell N, Carrie A, Zemni R, Couvert P, et al. Missense mutation in PAK3, R67C, causes X-linked nonspecific mental retardation. Am J Med Genet. 2000; 93: 294-8.
23. Chung EY, Mai Y, Shah UA, Wei Y, Ishida E, Kataoka K, et al. PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. Clin Cancer Res. 2019; 25: 3589-601.
24. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, et al. Colorectal cancer: mutations in a signalling pathway. Nature. 2005; 436: 792.
25. Chen S, Auletta T, Dovirak O, Hutter C, Kunz T, El-feti S, et al. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther. 2008; 7: 1793-802.
26. Li YX, Zou J, Ye DM, ZY, CK, CY, Luo GF, et al. Human p21-activated kinase 5 (PAK5) expression and potential mechanisms in relevant cancers: Basic and clinical perspectives for molecular cancer therapeutics. Life Sci. 2020; 241: 2387-95.
27. Tetley GJN, Mott HR, Couleyn RN, Owen D. A dock and coalesce mechanism driven by hydrophobic interactions governs Cdc24 binding with its effector protein ACK. J Cell Biol. 2017; 292: 11361-73.
28. Rowe W, Mott HR, LADE ED, LOWE PN. Resistances in Cdc24 that specify binding to individual CRIB effector proteins. Biochemistry. 2001; 39: 12430-5.
29. Mahajan K, Mahajan NP. ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers. Oncogene. 2015; 34: 4162-7.
30. Mahajan K, Mahajan NP. PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol. 2012; 227: 3178-84.
31. Xu SH, Huang JZ, Chen M, Zeng M, Zou FY, Chen, et al. Amplification of ACK1 promotes gastric tumorigenesis via ECD-dependent p53 ubiquitination degradation. Oncotarget. 2017; 8: 12075-6.
32. Krawczyk PA, Kowalski DM. Review Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Wspolczesna Onkologia. 2014; 1: 7-16.
33. Hamard C, Ruppert A-M, Lavole A, Rozenszajn N, Antoine M, Cadranel J, et al. Actualités sur les thérapies ciblées dans les cancers bronchiques non à petites cellules, hors immunothérapie. Annales de Bronchologie. 2016; 30: 63-72.
34. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, et al. PTK7-deficient cancers depend on PI3KCB. Proc Natl Acad Sci U S A. 2008; 105: 13057-62.
54. Mateer SC, Wang N, Bloom GS. IQGAPs: integrators of the cytoskeleton, cell adhesion machinery, and signaling networks. Cell Motil Cytoskel. 2003; 55: 147-55.

55. Rittmeyer EN, Daniel S, Hsu SC, Osman MA. A dual role for IQGAP1 in regulating p38 MAPK. J Cell Sci. 2008; 121: 403-10.

56. Parvathy M, Sreeja S, Kumar R, Pillai MR. Potential role of p21 activated kinase 1 (PAK1) in the invasion and motility of oral cancer cells. BMC Cancer. 2016; 16 Suppl 1: 293.

57. White CD, Brown MD, Sacks DB. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett. 2009; 583: 1817-24.

58. Hage R, Mettel K, Hsung P, Gielich K, Menke A. Rac1 activation inhibits E-cadherin-mediated adhesions junctions via binding to IQGAP1 in pancreatic carcinoma cells. Cell Commun Signal. 2009; 7: 23.

59. Jadeski L, Mataraza JM, Jeong HW, Li Z, Sacks DB. IQGAP1 stimulates proliferation and enhances tumorigenesis of human breast epithelial cells. J Biol Chem. 2008; 283: 1088-107.

60. Kuroda S, Fukata M, Nakagawa M, Fuji K, Nakamura T, Oooko T, et al. Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin-mediated cell-cell adhesion. Science. 1998; 281: 832-5.

61. Nabeshima K, Shimao Y, Inoue T, Koono M. Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: its overexpression in carcinomas and association with invasion fronts. Cancer Lett. 2002; 176: 101-9.

62. Nakamura H, Fukuji K, Nakagawa K, Kishi F, Takeuchi A, Aute I, et al. Expression pattern of the scaffold protein IQGAP1 in lung cancer. Oncol Rep. 2015; 34: 1293-9.

63. Li S, Wang Q, Chakladar A, Bronson RT, Bernards A. Gastric hyperplasia pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009; 5: e1000676.

64. Tanaka M, Kitajima Y, Edakuni G, Sato S, Miyazaki K. Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer. Br J Surg. 2002; 89: 236-44.

65. Le Clainche C, Schlaepfer D, Ferrari A, Klingauf M, Grohmanova K, Paul CD, et al. Bni1p, a yeast formin linking cdc42p and the actin cytoskeleton during polarized morphogenesis. Science. 1997; 276: 118-22.

66. Casiti TR, Waterman T, Sato K, Wang S, Kaibuchi K. IQGAP1: a key regulator of adhesion and migration. J Cell Sci. 2005; 118: 2085-92.

67. White CD, Khurana H, Gneretck DV, Li Z, Ozturk RD, Sacks DB, et al. IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol. 2010; 10: 125.

68. Nojima H, Adachi M, Matsui T, Okawa K, Tsukita S, Tsukita S. IQGAP3 regulates cell proliferation through the Ras/ERK signalling cascade. Nat Cell Biol. 2008; 10: 971-8.

69. Faix J, Grosse R. Staying in shape with formins. Dev Cell. 2006; 10: 693-26.

70. Evangelista M, Blundell K, Longtine MS, Chow CJ, Adames N, Pringle JR, et al. Cyk-1: a C. elegans FH gene required for a late step in embryonic limb deformity gene. Development. 1994; 120: 3367-77.

71. Rane CK, Minden A. P21 activated kinase signaling in cancer. Semin Cancer Biol. 2011; 21: 783-94.

72. Blessing NA, Brockman AL, Chadee DN. The E3 ligase CHIP mediates ubiquitination and degradation of mixed-lineage kinase 3. Mol Cell Biol. 2014; 34: 3132-43.

73. Zhan Y, Abi Saab WF, Modi N, Stewart AM, Liu J, Chadee DN. Mixed lineage kinase 3 is required for matrix metalloproteinase expression and invasion in ovarian cancer cells. Exp Cell Res. 2012; 318: 1641-8.

74. Bühn H, Legewie S. Analysis of MAPK signal transduction. Essays Biochem. 2008; 45: 95-107.

75. Mutavchiev DR, Leda M, Sawin KE. Remodeling of the Fission Yeast Cdc42 Cell-Polarity Module via the Sty1 p38 Stress-Activated Protein Kinase Pathway. Curr Biol. 2016; 26: 2921-8.

76. Shi L, Fu WY, Hung KW, Porchetta C, Hall C, Fu AK, et al. Alpha2-chimaerin interacts with Epha4 and regulates Epha4-dependent growth cone collapse. Proc Natl Acad Sci U S A. 2007; 104: 16347-52.

77. Hall C, Michael GJ, Cann N, Ferrari G, Teo M, Jacobs T, et al. Alpha2-chimaerin, a Cdc42/Rac1 regulator, is selectively expressed in the rat embryonic nervous system and is involved in neurogenesis in N18 neuroblastoma cells. J Neurosci. 2001; 21: 5191-202.

78. Libermann TA, Nusbaum HR, Razin N, Krets R, Lax I, Soreq H, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985; 313: 144-7.

79. Paul CD, Mistriotis P, Konstantopoulos K. Cancer cell motility: lessons from migration in confined spaces. Nat Rev Cancer. 2017; 17: 131-40.

80. Xiao XH, Lv LC, Duan J, Wu YM, He SJ, Hu ZZ, et al. Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates. Molecules. 2018; 23: 787.

81. Cai G, Long S, Zhai R, Zhang J, Cao M, Yuan J, et al. Cell adhesion machinery, and signaling networks. Cell Motil Cytoskel. 2003; 55: 147-55.
106. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 in breast cancer. Journal of Cancer. 2020; 11: 5656-62.

107. Zhang Y, Li J, Lai XN, Jiao XQ, Xiong JP, Xiong LX. Focus on Cdc42 in breast cancer: New Insights, Target Therapy Development and Non-Coding RNAs. Cells. 2019; 8: 146.

108. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119: 1420-8.

109. Bisson N, Wedlich D, Moss T. The p21-activated kinase Pak1 regulates Rac activation and inactivation control plasticity of tumor cell movement. Cell. 2008; 135: 510-23.

110. Fukata M, Kuroda S, Nakagawa M, Kawajiri A, Itoh N, Shoji I, et al. Rab27 effectors, pleiotropic regulators in secretory pathways. J Biol Chem. 1999; 274: 26044-50.

111. Zhang Z, Yang M, Chen R, Su W, Li P, Chen S, et al. IBP regulates Cdc42 and Rac1 regulate the interaction of IQGAP1 with beta-catenin. J Biol Chem. 1996; 271: 736-41.

112. Kawasaki Y, Tsuji S, Muroya K, Furukawa S, Shibata Y, Okuno M, et al. Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration. J Alzheimers Dis. 2018; 61: 1477-83.

113. Fukuda M. Rab27 effectors, pleiotropic regulators in secretory pathways. J Biol Chem. 1999; 274: 26044-50.

114. Yang JQ, Kalim KW, Li Y, Meng Y, Zheng Y, Guo F. Reciprocal Regulation of Glycolysis-Driven Th17 Pathogenicity and Regulatory T Cell Stability by Cdc42. J Immunol. 2018; 200: 2313-26.

115. Zhang PB, Liu Y, Li J, Kang QY, Tian YF, Chen XL, et al. ROCK, PAK, and Toll of neurodegeneration, from genetics to mechanisms. Nat Neurosci. 2018; 21: 1300-9.

116. Minard ME, Ellis LM, Gallick GE. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis. 2006; 23: 303-13.

117. Boulter E, Garcia-Mata R, Guilluy C, Dubash A, Rossi G, Brennwald PJ, et al. Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration. J Alzheimers Dis. 2018; 61: 1477-83.

118. Minard ME, Ellis LM, Gallick GE. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis. 2006; 23: 303-13.

119. Yiin JJ, Hu B, Jarzynka MJ, Feng H, Liu KW, Wu JY, et al. Silt2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity. Neuro Oncol. 2009; 11: 779-89.

120. Boulter E, Garcia-Mata R, Guilluy C, Dubash A, Rossi G, Brennwald PJ, et al. Regulation of Glycolysis-Driven Th17 Pathogenicity and Regulatory T Cell Stability by Cdc42. J Immunol. 2018; 200: 2313-26.

121. Yang JQ, Kalim KW, Li Y, Duan X, Nguyen P, Khurana Hershey GK, et al. Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation. Clin Exp Allergy. 2019; 49: 92-107.

122. Endo M, Druso JE, Cerione RA. The two splice variant forms of Cdc42 exert distinct and essential functions in neurogenesis. J Biol Chem. 2020; 295: 4498-512.

123. Gan L, Cookson MR, Petrucelli L, La Spada AR. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci. 2018; 21: 1300-9.

124. Saraceno C, Catania M, Paterlini S, Ciani M, Zanardini R, et al. Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration. J Alzheimers Dis. 2018; 61: 1477-83.

125. Salminen A, Suuronen T, Kaarniranta K. ROCK, PAK, and Toll of synapses in Alzheimer's disease. Biochim Biophys Res Commun. 2008; 371: 587-90.

126. Pelleieux X, Picard C, Lamarre-Theroux L, Dea D, Leduc V, Tsantrizos YS, et al. Isoprenoids and tau pathology in sporadic Alzheimer's disease. Neurobiol Aging. 2018; 65: 132-9.

127. Yeman KB, Isik S. Down regulation of DNA topoisomerase IIbeta exerts neurodegeneration like effect through Rho GTPases in cellular model of Parkinson's disease by Down regulating tyrosine hydroxylase. Neurol Res. 2021; 43: 464-73.

128. Hort J, O'Brien JT, Gainotti G, Piriltta T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010; 17: 1236-48.

129. Zins K, Lucas T, Reichl P, Abraham D, Aharinejad S. A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice. PLoS One. 2013; 8: e74924.

130. Zins K, Gunawardhana S, Lucas T, Abraham D, Aharinejad S. Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity. J Transl Med. 2013; 11: 295.

131. Peterson JR, Lehrman AM, Pelisch HE, Kirschner MW. Biochemical suppression of small-molecule inhibitors: a strategy to identify inhibitor targets and signaling pathway components. Chem Biol. 2006; 13: 43-52.

132. Florian MC, Dorr K, Niebel A, Daria D, Schrezenmeier H, Rojewski M, et al. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell. 2012; 10: 520-30.

133. Sakamori R, Das S, Yu S, Feng S, Stypulkowski E, Guan Y, et al. Cdc42 and Rab8a are critical for intestinal stem cell survival, diversification, and differentiation in mice. J Clin Invest. 2012; 122: 1052-65.
157. Ndubaku CO, Crawford JJ, Drobnick J, Aliagas I, Campbell D, Dong P, et al. Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pKa Polar Moiety. ACS Med Chem Lett. 2015; 6: 1241-6.

158. Humphries-Bickley T, Castillo-Pichardo L, Hernandez-O’Farrill E, Borrono-García LD, Forestier-Roman I, Gerena Y, et al. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer. Mol Cancer Ther. 2017; 16: 805-18.

159. Maruta H, Ahn MR. From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy. Eur J Med Chem. 2017; 142: 229-43.

160. McCoull W, Henneasy EJ, Blades K, Chuauqi C, Dowling JE, Ferguson AD, et al. Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. ACS Med Chem Lett. 2016; 7: 1118-23.

161. Yeo D, He H, Patel O, Lowy AM, Baldwin CS, Nikfarjam M. FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. BMC Cancer. 2016; 16: 24.

162. Licciulli S, Maksinoska J, Zhou C, Troutman S, Kota S, Liu Q, et al. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem. 2013; 288: 29108-15.

163. Polish HE, Westwood NJ, Feng Y, Kirchhausen T, Shair MD. Use of biomimetic diversity-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product. J Am Chem Soc. 2001; 123: 6740-1.

164. Sorber R, Teper Y, Abisoye-Ogunniyan A, Waterfall JJ, Davis S, Killian JK, et al. Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. PLoS One. 2016; 11: e0149833.

165. Zhan Y, Liang X, Li L, Wang B, Ding F, Li Y, et al. MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1. Mol Oncol. 2016; 10: 838-49.

166. Surviladze Z, Waller A, Strouse JJ, Bologa C, Ursu O, Salas V, et al. A Potent and Selective Inhibitor of Cdc42 GTPase. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD)National Center for Biotechnology Information (US); 2010 -. p. 1-27.

167. Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, et al. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis. Mol Cancer Ther. 2015; 14: 2215-27.

168. Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Noth J, et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem. 2013; 288: 8531-43.

169. Guo Y, Kenney SR, Cook L, Adams SF, Rutledge T, Romero E, et al. A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients: Clin Cancer Res. 2013; 21: 5064-72.

170. Ho HY, Rohatgi R, Lebensohn AM, Le M, Li J, Gygi SP, et al. Toca-1 mediates Cdc42-dependent actin nucleation by activating the N-WASP-WIP complex. Cell. 2004; 118: 203-16.

171. Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal. 1999; 11: 545-54.

172. Musch A, Cohen D, Kreitzer G, Rodriguez-Boulan E. cdc42 regulates the exit of apical and basolateral proteins from the trans-Golgi network. EMBO J. 2001; 20: 2171-9.

173. Polish HE, Peterson JR, Salparezsa SB, Rodriguez-Boulan E, Chen JL, Stannnes M, et al. Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro. Nat Chem Biol. 2006; 2: 39-46.

174. Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Noth J, et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem. 2013; 288: 8531-43.